Hesse U J, Berrevoet F, Troisi R, Pattyn P, Mortier E, Decruyenaere J, de Hemptinne B
Department of Surgery, University Hospital Gent, Belgium.
Langenbecks Arch Surg. 2000 Aug;385(5):350-6. doi: 10.1007/s004230000149.
The potential advantages of vena cava-preserving recipient hepatectomy in orthotopic liver transplantation are reduced hemorrhage, improved cardiovascular stability and preserved renal perfusion without the requirement of veno-venous bypass as compared with recipient hepatectomy including the vena cava. No detailed information is available on the use of veno-venous bypass during complicated vena cava preserving recipient hepatectomy and liver transplantation. In the present study, the peri- and postoperative courses of adult liver transplant recipients in whom the hepatovenous reconstruction was performed according to three different techniques with and without the use of veno-venous bypass were investigated.
PATIENTS/METHODS: During primary orthotopic liver transplantation, an end-to-end (ETE) cavo-caval interposition of the donor vena cava to the recipient's vena cava was performed in 75 patients (group I). In 15 patients, a termino-terminal piggyback (PB) anastomosis was constructed to the remnant of the recipient's hepatic vein (group II), and in 72 transplantations a latero-lateral cavo-cavostomy (LLC) of donor-to-recipient's vena cava (group III) was performed. The use of bypass, operative time and cold ischemia time, perioperative blood product requirements, incidence of relaparotomy, the evolution of postoperative renal function, technical complications and the survival were analyzed and compared using multivariate statistics and actuarial techniques for statistical evaluation.
No differences could be found in preoperative patient conditions, donor conditions, operating time, anastomosing time or cold ischemia time. In groups I-III, the veno-venous bypass was used in 50 (67%), 8 (53%) and 6 (8%) cases respectively (P=0.02 for group III). The mean preoperative packed cells requirements were 20.4 vs 29.6 vs 10.8 units (P=0.01 for group III), while postoperative blood product requirements (first 24 h) were 2.6 vs 5.0 vs 0.20 units of packed cells (P=0.02 for group III). Relaparotomy for diffuse retroperitoneal hemorrhage was performed 14 times (19%) in group I, 3 times (20%) in group II and 7 times (8.3%) in group III (P=0.002). The incidence of posteropative early renal dysfunction (increase of > or =1.3 mg% serum creatinine) in group I vs group II vs group III was 24% vs 60% vs 16.7% (P=0.001 for group II) for patients without the use of veno-venous bypass. No significant difference was observed concerning early renal dysfunction in patients where a veno-venous bypass was used. The survival at 12 months was 81% for group I, 86% for group II and 93.0% for group III. In group III there were four complications (P=0.03) at the hepatovenous anastomosis of which two were eventually fatal.
Preservation of the recipient's vena cava and LLC can reduce, but not avoid, the requirement for veno-venous bypass. In orthotopic liver transplantation, postoperative hemorrhage, as measured by surgical revisions and requirement for blood products, is significantly reduced with LLC with and without bypass. Early renal dysfunction also occurs in the group of LLC as compared with the termino-terminal cavostomy independent of the bypass. A technical failure resulting in patient death can be associated with LLC.
与包含腔静脉的受体肝切除术相比,原位肝移植中保留腔静脉的受体肝切除术具有减少出血、改善心血管稳定性以及在无需静脉-静脉转流的情况下保持肾灌注的潜在优势。目前尚无关于复杂的保留腔静脉受体肝切除术及肝移植过程中使用静脉-静脉转流的详细信息。在本研究中,我们调查了采用三种不同技术进行肝静脉重建且使用或未使用静脉-静脉转流的成年肝移植受者围手术期及术后的情况。
患者/方法:在初次原位肝移植过程中,75例患者(I组)进行了供体腔静脉与受体腔静脉的端端(ETE)腔静脉间置术。15例患者(II组)构建了供体与受体肝静脉残端的端端背驮式(PB)吻合,72例移植手术(III组)进行了供体与受体腔静脉的侧侧腔静脉吻合术(LLC)。使用多变量统计和精算技术对转流的使用情况、手术时间和冷缺血时间、围手术期血液制品需求、再次剖腹手术发生率、术后肾功能变化、技术并发症及生存率进行分析和比较,以进行统计学评估。
术前患者情况、供体情况、手术时间、吻合时间或冷缺血时间方面未发现差异。在I - III组中,分别有50例(67%)、8例(53%)和6例(8%)使用了静脉-静脉转流(III组P = 0.02)。术前平均红细胞压积需求分别为20.4单位、29.6单位和10.8单位(III组P = 0.01),而术后血液制品需求(最初24小时)分别为2.6单位、5.0单位和0.20单位红细胞压积(III组P = 0.02)。I组因弥漫性腹膜后出血进行再次剖腹手术14次(19%),II组3次(20%),III组7次(8.3%)(P = 0.002)。未使用静脉-静脉转流的患者中,I组、II组和III组术后早期肾功能不全(血清肌酐升高≥1.3mg%)的发生率分别为24%、60%和16.7%(II组P = 0.001)。使用静脉-静脉转流的患者在早期肾功能不全方面未观察到显著差异。I组12个月生存率为81%,II组为86%,III组为93.0%。III组在肝静脉吻合处有4例并发症(P = 0.03),其中2例最终死亡。
保留受体腔静脉及LLC可减少但不能避免静脉-静脉转流的需求。在原位肝移植中,无论是否使用转流,LLC均能显著减少通过手术修正和血液制品需求衡量的术后出血。与端端腔静脉吻合术相比,LLC组无论是否使用转流均会出现早期肾功能不全。LLC可能会导致技术失败并造成患者死亡。